You can add Novartis (NVS) to the list of drug makers settling allegations that donations made to patient charities amounted to kickbacks paid to Medicare patients as a way to cover their out-of-pocket costs.

The company reached an agreement in principle to pay $23 million in response to a probe opened three years ago by the U.S. Attorney in Boston regarding assistance provided to Medicare patients who were prescribed various medicines, including the Gleevec cancer medicine and the Gilenya multiple sclerosis treatment, according to its latest annual report. The settlement was not previously disclosed.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Would be helpful to understand how exactly these pharma companies did something wrong. The fact is that financial assistance for patients critical for the delivery of care. If the Federal government wants to control drug costs they should fix Medicare part D. It is my understanding that the federal government can not negotiate drug prices with PHARMA companies . They should fix this as opposed to harming patients who can not afford copays that oncology patients frequently are more than 1,000 dollars per month. If the FEDS want to shake down PHARMA companies they will turn around and simply increase the price of their drugs. This current move by the FEDS is irrational and end result injured patients

    Steve Mamus MD
    Cancer Center of Sarasota

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy